Pancreatic Cancer Research

ResearcherUniversity of North Carolina at CharlotteNo recent work listed

Mukulika Bose

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2347-7413; OpenAlex author ID A5043466920. Sources: OpenAlex.

Their work

Papers
5 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 5

  1. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer. Co-author DOI 10.1016/j.trsl.2022.08.010↗
  2. Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fcell.2022.821875↗
  3. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models First author DOI 10.3390/ijms22115587↗
  4. Tumor -Associated MUC1 Regulates TGF-β Signaling and Function in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.1101/2020.04.29.068577↗
  5. Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells8091070↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pinku Mukherjee · 5 shared papers, 2019–2023 · strength 0.66
  2. Ru Zhou · 4 shared papers, 2019–2023 · strength 0.52
  3. Sritama Nath · 3 shared papers, 2020–2022 · strength 0.39
  4. Priyanka Grover · 3 shared papers, 2019–2022 · strength 0.34
  5. Mahboubeh Yazdanifar · 3 shared papers, 2019–2022 · strength 0.34
  6. Shu-ta Wu · 2 shared papers, 2019–2020 · strength 0.19
  7. Mahnaz Sahraei · 1 shared paper, 2021 · strength 0.14
  8. John F. Maher · 1 shared paper, 2019 · strength 0.09
  9. Didier Dréau · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.